US FDA and personalized medicine: in vitro diagnostic regulatory perspective

Author： Težak Živana   Kondratovich Marina V   Mansfield Elizabeth  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.7, Iss.5, 2010-09, pp. : 517-530

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulatory Focus: Bringing home the genome: the US FDA’s role in realizing personalized medicine

By Hamburg Margaret  

Personalized Medicine, Vol. 7, Iss. 3, 2010-05 ,pp. : 239-242

Future Medicine

Access to resources Recommend Favorite

Genomics and personalized medicine: a perspective

By Desnick Robert J  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 135-137

Future Medicine

Access to resources Recommend Favorite

Regulatory and ethical challenges of personalized medicine

By Torr-Brown Sheryl R  

Personalized Medicine, Vol. 7, Iss. 5, 2010-09 ,pp. : 465-468

Future Medicine

Access to resources Recommend Favorite

Innovative Diagnostic Technologies and Their Significance for Personalized Medicine

By Jain Kewal K.  

Molecular Diagnosis & Therapy, Vol. 14, Iss. 3, 2010-06 ,pp. : 141-147

Adis International

Access to resources Recommend Favorite

Translation of psychoneuroimmunology into personalized medicine: a systems biology perspective

By Yan Qing  

Personalized Medicine, Vol. 8, Iss. 6, 2011-11 ,pp. : 641-649

Future Medicine

Access to resources Recommend Favorite